Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study.

ABSTRACT:

Objective

To determine the efficacy and safety of linagliptin in initial combination with metformin in patients with type 2 diabetes.

Methods

This 1-year randomised, double-blind study was an extension of a 6-month randomised controlled trial, in which adults with type 2 diabetes received one of six treatment regimens (linagliptin 2.5 mg plus metformin 500 mg bid, linagliptin 2.5 mg plus metformin mg 1000 bid, metformin 1000 mg bid, metformin 500 mg bid, linagliptin 5 mg qd or placebo). In the extension, patients in the first three treatment groups continued their regimen (non-switched group, n = 333) while the metformin 500 mg bid, linagliptin 5 mg qd and placebo groups were re-randomised to one of the three continuing regimens (switched group, n = 233).

Results

All

SUBMITTER: Haak T 

PROVIDER: S-EPMC4282285 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature